Evidence map›Paper›PMID 26951513›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

MicroRNA-183 promotes migration and invasion of CD133(+)/CD326(+) lung adenocarcinoma initiating cells via PTPN4 inhibition.

Conghui Zhu, Xi Deng, Jingbo Wu, Jianwen Zhang, Hongru Yang, Shaozhi Fu, Yan Zhang, Yunwei Han, Yuanmei Zou, Zhengtang Chen and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. miR-183 promotes radioresistance of lung adenocarcinoma H1299 cells via epithelial-mesenchymal transition.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2021
    Article
  8. MicroRNA-183 in Cancer Progression.Journal of Cancer · 2020
    Review
  9. Article
  10. Integrated analysis and knockdown ofAnnals of translational medicine · 2019
    Article
  11. Article
  12. Article
  13. Article
  14. The correlation of PTPN4 expression with prognosis in breast cancer.International journal of clinical and experimental pathology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Conghui ZhuInstitute of Cancer, Xiqiao Hospital, Third Military Medical University, Chongqing, 40037, China.
Xi DengDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, China.
Jingbo WuDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, China.
Jianwen ZhangDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, China.
Hongru YangDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, China.
Shaozhi FuDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, China.
Yan ZhangNuclear Medicine Department, The First Affiliated Hospital of Sichuan Medical University, Luzhou, Sichuan, 646000, China.
Yunwei HanDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, China.
Yuanmei ZouDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, China.
Zhengtang ChenInstitute of Cancer, Xiqiao Hospital, Third Military Medical University, Chongqing, 40037, China. zhengtangchen@126.com.
Sheng LinDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, China. lslinsheng@163.com.
Affiliated Hospital of Southwest Medical University · CNArmy Medical University · CNFirst Affiliated Hospital of Sichuan Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-small cell lung cancer (NSCLC) is the most common cancer worldwide and is a leading cause of lung cancer mortality due to early stage metastases. Cancer stem-like cells (CSLCs) or tumor-initiating cells (TICs) are rare subpopulation cells that are responsible for maintaining tumor growth and invasion leading to recurrence and metastasis. Previous studies revealed that miR-183 can mediate the invasiveness and growth of NSCLC. However, the exact role of miR-183 in regulating the biological behavior of CSLCs in NSCLC remains unclear. In the present study, we explored the regulation of protein tyrosine phosphatase non-receptor type 4 (PTPN4) by miR-183 in vitro using luciferase reporter assays, and we further analyzed the effects of miR-183 on the invasiveness of CSLCs in vitro and in vivo using transwell and bioluminescence assays. Following our finding that miR-183 binds to PTPN4 messenger RNA (mRNA) to prevent its translation through the 3'-untranslated region (UTR), we found that overexpression of miR-183 in CSLCs decreased PTPN4 protein levels while inhibition of miR-183 increased PTPN4 protein levels. The suppression of PTPN4 levels in CSLCs by miR-183 paralleled with a significant promotion in their motility in vitro and in vivo, while anti-sense miR-183 increased PTPN4 levels in CSLCs, which paralleled with a significant decrease in their invasiveness. Furthermore, correlation analysis between miR-183 and PTPN4 in clinical samples demonstrated a statistically significant inverse correlation between PTPN4 mRNA levels and miR-183. In brief, our data indicate that miR-183 plays a pro-invasive role by inverse regulation of PTPN4, and this axis may be a new therapeutic target for suppressing the metastatic capability of CSLCs in NSCLC.

Indexed as

AC133 AntigenAdenocarcinomaAdenocarcinoma of LungAnimalsBlotting, WesternCell Line, TumorCell MovementEpithelial Cell Adhesion MoleculeFlow CytometryFluorescent Antibody TechniqueGene Expression Regulation, NeoplasticHeterograftsHumansLung NeoplasmsMiceMice, NudeAC133 AntigenEpithelial Cell Adhesion MoleculeMicroRNAsMIRN183 microRNA, humanPROM1 protein, humanProtein Tyrosine Phosphatase, Non-Receptor Type 4PTPN4 protein, humanCancer stem-like cellsCD133/CD326miR-183PTPN4Tumor-initiating cells

Identifiers

PMID26951513
OpenAlexW2306942974

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.